Image not available
Chemicals
MART-1(27-35), human CAS NO.156251-11-5
<p>MART-1(27-35), Human (CAS 193062-65-6) is a research-grade, HLA-A*0201-restricted epitope peptide with a molecular formula of C₄₉H₇₅N₁₃O₁₁ and a molecular weight of 1042.22 g/mol. Manufactured to ≥98% purity via RP-HPLC, it is a key tool for studying melanoma immunogenicity, T-cell activation, and cancer vaccine development.<br/></p>
SupplierGlobal Technology Co., Ltd.www.hqtechtirz.com
Source categories
About this product
Product information from the supplier.
TECHNICAL SPECIFICATIONS
| Item | Specification |
|---|---|
| Product Name | MART-1(27-35), Human |
| CAS NO. | 156251-11-5 |
| Appearance | White to off-white lyophilized powder |
| Molecular Formula | C37H67N9O11 |
| Molecular Weight | 814g/mol |
| Purity (RP-HPLC) | ≥ 95.0% |
| Solubility | Soluble in water (≥5 mg/mL), dilute acetic acid, or 0.01M PBS |
| Endotoxin | < 1.0 EU/mg |
| Biological Activity | Functions as a melanoma-specific HLA-A*0201-restricted epitope, capable of inducing and activating cytotoxic T lymphocytes (CTLs) that target melanoma cells. Validated for use in cancer immunology research and vaccine development studies. |
| Storage Conditions | -20°C to -80°C in a desiccated environment, avoiding repeated freeze-thaw cycles. |
| Stock Location | Stock in USA |
| MOQ | 1g |
1.MECHANISM OF ACTION
This peptide acts as a melanoma-specific antigenic epitope. It binds to the HLA-A*0201 molecule on antigen-presenting cells (APCs) to form a peptide-MHC complex. This complex is recognized by CD8⁺ cytotoxic T lymphocytes (CTLs), triggering CTL activation, proliferation, and targeted killing of MART-1-expressing melanoma cells. This mechanism is central to tumor immune surveillance and the development of cancer immunotherapies.
2.PRODUCT INDICATIONS
Melanoma tumor immunogenicity and T-cell response assays
Preclinical development of peptide-based cancer vaccines
Validation of HLA-A0201-restricted epitope presentation
Immunotherapy efficacy testing in in vitro and in vivo models
Mechanistic research into tumor escape from immune surveillance
3.CLINICAL EFFICACY OF PRODUCT
It reliably induces melanoma-specific CTL responses in HLA-A*0201-positive individuals.In vaccine trials, it has shown potential to shrink tumors and delay disease progression in melanoma patients.It has been used to monitor minimal residual disease and immune response persistence in post-treatment patients.It is a foundational component in the development of personalized cancer immunotherapies.
4.DELIVERY & SHIPPING
We specialize in global logistics for various cosmetic peptides. Your order will be handled with the utmost care, ensuring safe, reliable, and intact delivery.
Professional and Secure Packaging
Each bottle of peptide is protected with a special packaging solution to ensure stability and integrity during transportation.
We can also customize packaging according to customer needs.
Shipping Methods
Main Method: International Air Freight
We primarily use DHL, FedEx, UPS, and TNT because of their global reliability, speed, and advanced tracking systems. Air freight ensures the fastest transit time and minimizes the impact of environmental factors on the product.
More from this supplier
Global Technology Co., Ltd.
